Key result
Patients with major depressive disorder had significantly higher COMPASS-31 scores compared to healthy controls (22.56 vs 7.6, p=0.0001), indicating a greater burden of dysautonomia.
Why the study?
Depression affects cognitive functions and is a risk factor for sudden cardiac death, prompting the use of COMPASS-31 to quantify autonomic symptoms in patients with depression.
Does the COMPASS-31 scale identify increased dysautonomia symptoms in patients with major depressive disorder compared to healthy controls?
Cross-Sectional (n=84)
Yes
Does the COMPASS-31 scale identify increased dysautonomia symptoms in patients with major depressive disorder compared to healthy controls?
Absolute Event Rate: 22.56% vs 7.6%
p-value: p=0.0001
Patients with major depressive disorder exhibit significantly higher self-reported autonomic dysfunction scores on the COMPASS-31 scale compared to healthy controls.
May support autonomic symptom screening in MDD; hypothesis-generating for causality and management trials.
Background Dysautonomia denotes an alteration in the autonomic nervous system that can significantly lead to multiorgan failure. Conversely, depression not only affects cognitive functions but also poses a risk factor for sudden cardiac death. In our study, the Composite Autonomic Scoring-31 (COMPASS-31) is used to quantify the autonomic symptoms present if any in patients with depression. Materials and methods Forty-two patients with major depressive disorder (MDD) were recruited using a PHQ-9 questionnaire followed by a COMPASS-31 scale to quantify dysautonomia symptoms, and they were compared with healthy controls. Further regression analysis was conducted to establish any relationship between independent variables and COMPASS-31 scores. Results The average COMPASS-31 score in patients with MDD was 22.56±8.42, which was significantly increased compared to healthy controls (p=0.001). Furthermore, the differences persisted across various subdomains of the COMPASS-31 scale relative to severity of depression. Conclusion The study observations could provide a relevant perception regarding the association between depression and autonomic dysfunction with the use of a simple and brief yet validated instrument COMPASS-31, which can be utilized for screening at the primary care level.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2023) conducted a cross-sectional in Major Depressive Disorder (n=84). Major Depressive Disorder vs. Healthy controls was evaluated on COMPASS-31 score (p=0.0001). Patients with major depressive disorder had significantly higher COMPASS-31 scores compared to healthy controls (22.56 vs 7.6, p=0.0001), indicating a greater burden of dysautonomia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: